Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 10, pp 1467–1468 | Cite as

No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report

  • Dario CattaneoEmail author
  • Marta Fusi
  • Cristina Gervasoni
Letter to the Editor
  • 57 Downloads

Hypericum perforatum is an herbal product that is commonly used in the treatment of depression [1]. Its antidepressant effect is mediated by hyperforin, a phytochemical which inhibits the reuptake of several neurotransmitters in the synapses [2]. Beside the antidepressant activity, Hypericum can cause relevant drug-drug interactions (DDIs) [3, 4].

Dolutegravir is a key component of first-line treatments for naïve and experienced HIV-infected patients [5]. According to the drug monograph, co-administration of dolutegravir with Hypericum-containing supplements is strongly discouraged. If such combination cannot be avoided, dose of dolutegravir should be doubled [6]. However, such recommendation is predicted based on the inductive effect of this supplement on metabolic enzymes, and pharmacokinetic data are lacking.

A 42-year-old man was diagnosed HIV-positive in 2007. After the diagnosis, the antiretroviral therapy was deferred up to December 2015, when CD4+ cell count dropped to less...

Notes

Contribution of the authors

DC and CG supervised all the stages of the study and wrote the first draft of the manuscript. MF performed pharmacokinetic analyses and revised the draft manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, Patanè M, Upton R, Pugliese M, Chimirri S, Mammì M, Palleria C, de Sarro G (2014) Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res 28:643–655CrossRefGoogle Scholar
  2. 2.
    Di Carlo G, Borrelli F, Ernst E, Izzo AA (2001) St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22:292–297CrossRefGoogle Scholar
  3. 3.
    Brooks KM, George JM, Kumar P (2017) Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. Expert Rev Clin Pharmacol 10:59–79CrossRefGoogle Scholar
  4. 4.
    Borrelli F, Izzo AA (2009) Herb-drug interactions with St John’s wort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710–727CrossRefGoogle Scholar
  5. 5.
    Cattaneo D, Capetti A, Rizzardini G (2019) Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol 15:245–252CrossRefGoogle Scholar
  6. 6.
    Tivicay Product Monograph - ViiV Healthcare Canada. Available at https://www.viivhealthcare.ca/media/151925/tivicay.pdf (last access June 6, 2019)
  7. 7.
    Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97:7500–7502CrossRefGoogle Scholar
  8. 8.
    Mannel M (2004) Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 27:773–797CrossRefGoogle Scholar
  9. 9.
    Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ (2019) Understanding drug interactions with St John’s wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol 71:129–138CrossRefGoogle Scholar
  10. 10.
    Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A et al (2019) SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother 74:1035–1043CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Gestione Ambulatoriale Politerapie (GAP) outpatient clinicASST Fatebenefratelli Sacco University HospitalMilanItaly
  2. 2.Unit of Clinical PharmacologyASST Fatebenefratelli Sacco University HospitalMilanItaly
  3. 3.Department of Infectious DiseasesASST Fatebenefratelli Sacco University HospitalMilanItaly

Personalised recommendations